Current therapy strategies of the German Hodgkin Study Group (GHSG);Aktuelle therapiestrategien der Deutschen Hodgkin Studiengruppe (GHSG)

Onkologe

Volumn 16, Issue 1, 2010, Pages 28-34

  Engert, A ^a  

^a Klinik III fur Innere Medizin   (Germany)

Author keywords

BEACOPP eskaliert; Chemotherapy; Involved field; Patients with Hodgkin's lymphoma; PET

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; GRANULOCYTE COLONY STIMULATING FACTOR; HCD 122; LENALIDOMIDE; OFATUMOMAB; PANOBINOSTAT; PREDNISONE; PROCARBAZINE; RITUXIMAB; SGN 35; UNCLASSIFIED DRUG; VINBLASTINE SULFATE; VINCRISTINE; VINCRISTINE SULFATE;

ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL RESEARCH; DRUG MECHANISM; HODGKIN DISEASE; HUMAN; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION DOSE;

EID: 77951208876     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-009-1769-y     Document Type: Article

References (10)

1. Engert A, Franklin J, Eich HT et al for the German Hodgkin's Study Group (GHSG) (2007) Two cycles of ABVD plus extended field radiotherapy is superior to radiotherapy alone in early-favourable hodgkin lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol 10;25(23):3495-3502
2. Noordijk EM, Carde P, Dupouy N et al (2006) Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24:3128-3135 (Pubitemid 46638951)
3. Hagenbeek A, Eghbali H, Fermé C et al (2000) Three cycles of MOPP/ABV (M/A) hybrid and involved-field irradiation is more effective than subtotal nodal irradiation (STNI) in favourable supradiaphragmatic clinical stages (CS) I-II Hodgkin's disease (HD): Preliminary results of the EORTC-GELA H8-F randomized trial in 543 patients. Blood 11:2472
4. Engert A, Schiller P, Josting A et al (2003) Involved field (IF) radiotherapy is equally effective and less toxic as compared with extended field (EF) radiotherapy after 4 cycles of chemotherapy in patients with early-stage unfavourable Hodgkin's lymphoma - Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group (GHSG). J Clin Oncol 21(19):3601-3608 (Pubitemid 46594052)
5. Fermé C, Eghbali H, Meerwaldt J et al (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease for the EORTC-GELA H8 trial. N Engl J Med 357:1916-1927
6. Diehl V, Re D, Harris NL et al (2008) Hodgkin Lymphoma. In: Vita V de (ed) Cancer principles & practice of oncology, Vol 2, Lymphomas, Sec 5:2167-2213
7. Diehl V, Franklin J, Pfreundschuh M et al (2003) Standard and encreased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 12(24) 348:2386-2395 (Pubitemid 36682817)
8. escalated in the treatment of patients with advanced-stage Hodgkin Lymphoma: 10 years follow-up of the GHSG HD9 study*. *This work is dedicated to Professor Volker Diehl. J Clin Oncol [Epub ahead of print]
9. Kobe C, Dietlein M, Franklin J et al (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin Lymphoma. Blood 112:3989-3994
10. Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107(1):52-59 (Pubitemid 43053523)